22 Apr 2023 1

Vinnova 2012-11-01Samuel SvenssonPeter StrömCarl M Andersson

Enabling rapid and simple radiolabeling of biologicalsRadTag multimodal bioimaging

Delivered 3 amyloid PET ligands to clinical testing

Nature (2008) 456

RadTags simplify radiolabeling of biologicals

Enabling• Increased flexibility and specific binding• Stable binding – small tag size reduces interference with

target protein• PKPD studies with labeled proteins• Companion diagnostics• Potential for pre-targeting

”Agents and methods for visualising analytes ”PCT/EP2011/070172 IPR fully owned by BioPercept

Biologicals are must have for pharmaSix out of 24 new approvals by the FDA were for biologicals in 2011-- share will increase; typical pharma ambition calls for 30-40% of pipeline

Radiolabeling within development of biologicals is very limited -- lack of generalised radiochemical methodology

Biosimilars market estimated at USD 4,000 million in 2017

Increasing demand for ability to monitor, visualise, perform PK studies

RadTags trigger a paradigm shift

See Statement of interest (back ups)

FlAsH technology – a fluorescence labeling technology developed for live cell imaging (R Tsien Nobel prize 2008)

FlAsH-based protein detection available from

RadTags bind to same consensus sequence as FlAsHNon-invasive, clean, targeted technique

The CCPGCC tag can be incorporated by standard techniques– During peptide synthesis– Using Polymerase chain reaction (PCR)– Using commercially available cloning vectors from Life Technologies

PromotorGene

CCPGCC tag (in frame)

Expression vector

Easily constructed six-amino acid tags

RadTags enable radiolabelling using different isotopes at the same site, Multimodal

Precursor for 18F, 121I, 125I, 131I,

Precursor for 13C, 14C, 11C, 3H, 19F

Flourescence

Preclin summary

RadTag

• form rapid and covalent binding with CCPGCC-peptides• can rapidly be radiolabeled with [14C] & [3H]• bound to modifed a-MSH peptide retain pharmacological potency

Commercial: InnovationskontorEtt LiUTechnical PoC: Prof Victor Hruby

Ac-Nle-Asp-His-(D)Phe-Arg-Trp-Gly-Lys-Arg-Trp-Cys-Cys-Pro-Gly-Cys-Cys-Lys-Thr-Phe

Cheng et al J Nucl Med 2007; 48:987–994

PoC study: PET Melanoma

RadTag-MSH [125I]NDP-a-MSH at hMCR1

RadTag-a-MSH retain same binding profile as a-MSH

PoC study: PET Melanoma

Samuel Svensson, PhD• Professor of Pharmacology, LiU. Principal scientist

AstraZeneca R&D. Project leader PET ligand project 2004-2011 (AZD2184, 2995, 4694).

Chairman BioPercept

Peter Ström, MSc• Radiochemist with 20+ years experience within

AstraZeneca. CSO radiochemistry BioPercept

Carl M Andersson, PhD, associate professor• Organic chemist. Consultant with 20+ years experience

from senior managerial positions within biotech and pharma. CEO BioPercept

The Team

Åsa Wallin Affärsutvecklare InnovationskontorEtt LiU

• Innovationsbron• Innovationskontoret, LiU, Maria Swartz• Competence Network AB, Södertälje• Prof Peter Konradsson, Organic Chemistry LiU

Financing and partners

www.biopercept.com